person · Reporting owner
Stewart Christopher P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aeluma, Inc.ALMU · Entity 6202 | Chief Financial Officer | September 30, 2026 | October 02, 2026 |
| Bionano Genomics, Inc.BNGO · Entity 7831 | Chief Financial Officer | May 12, 2023 | May 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aeluma, Inc.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,781 |
Reported balance
After 2026-09-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-30 · Tax withholding · Disposed 5,697 · Balance 67,781 F1: Includes 41,250 additional shares issuable upon vesting and settlement of existing RSUs that were previously reported in Table II. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 41,250 additional shares issuable upon vesting and settlement of existing RSUs that were previously reported in Table II.
Bionano Genomics, Inc.
Report date May 12, 2023 · Filed May 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 281,373 |
Reported balance
After 2023-05-12 transaction · row 1
1 source rowRow 1 · 2023-05-12 · Purchase · Acquired 50,000 · Balance 281,373 F1: The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6682 to $0.6683, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6682 to $0.6683, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 05:31 UTC | Aeluma, Inc. ALMU · Entity 6202 | Tax withholdingCommon Stock | 5,697 | $12.36 | $70,414.92 |
DisclosureSEC source: 0001822991-26-000005 · form4-10022026_011020.xml · nonDerivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,781 F1 · balance_after: Includes 41,250 additional shares issuable upon vesting and settlement of existing RSUs that were previously reported in Table II. Read SEC document |
| September 21, 2026 Filed Sep 23, 2026 23:18 UTC | Aeluma, Inc. ALMU · Entity 6202 | GrantStock Option (right to buy) · Derivative | 37,568 | $0.00 Strike: $13.61 | $0.00 |
DisclosureSEC source: 0001822991-26-000003 · form4-09232026_110915.xml · derivative · entry 4 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,568 Underlying: Common Stock · 37,568 shares Expires 2036-09-21 F3 · derivative.exercise_date: Stock options scheduled to vest with respect to 25% of the shares on first anniversary of the grant date, and thereafter in 36 substantially equivalent increments on each monthly anniversary of the grant date. Read SEC document |
| September 21, 2026 Filed Sep 23, 2026 23:18 UTC | Aeluma, Inc. ALMU · Entity 6202 | Tax withholdingCommon Stock | 1,450 | $13.61 | $19,734.50 |
DisclosureSEC source: 0001822991-26-000003 · form4-09232026_110915.xml · nonDerivative · entry 3 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,478 Read SEC document |
| September 21, 2026 Filed Sep 23, 2026 23:18 UTC | Aeluma, Inc. ALMU · Entity 6202 | GrantCommon Stock | 4,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001822991-26-000003 · form4-09232026_110915.xml · nonDerivative · entry 2 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,928 F2 · shares: Stock award in lieu of cash bonus. Read SEC document |
| September 21, 2026 Filed Sep 23, 2026 23:18 UTC | Aeluma, Inc. ALMU · Entity 6202 | GrantCommon Stock | 15,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001822991-26-000003 · form4-09232026_110915.xml · nonDerivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,886 F1 · shares: Restricted stock units ("RSUs") scheduled to vest and settle into an equal number of shares of common stock with respect to 25% of the shares on September 30, 2027 and thereafter in 12 substantially equivalent quarterly increments on the last day of each calendar quarter. Read SEC document |
| May 12, 2023 Filed May 16, 2023 22:22 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 50,000 | $0.67 | $33,415.00 |
DisclosureSEC source: 0001411690-23-000031 · wf-form4_168427572747814.xml · nonDerivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,373 F1 · price: The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6682 to $0.6683, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:20 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 490,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-23-010918 · doc4.xml · derivative · entry 2 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,000 Underlying: Common Stock · 490,000 shares Expires 2033-02-14 F3 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2023 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:20 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010918 · doc4.xml · nonDerivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,373 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes 2,285 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2022 and 2,509 shares acquired under the ESPP on December 10, 2022. Read SEC document |
| May 13, 2022 Filed May 17, 2022 01:31 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-22-029459 · doc4.xml · derivative · entry 2 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,500 Underlying: Common Stock · 60,000 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares vest in full on December 31, 2020, subject to Reporting Person's continuous service through December 31, 2020, subject to acceleration of vesting provided in the Employment Agreement, dated as of September 1, 2020, by and between the Issuer and the Reporting Person. Read SEC document |
| May 13, 2022 Filed May 17, 2022 01:31 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Exercise / conversionCommon Stock | 60,000 | $0.56 | $33,600.00 |
DisclosureSEC source: 0001209191-22-029459 · doc4.xml · nonDerivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 3,139 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2021 and 2,940 shares acquired under the ESPP on December 10, 2021. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 02:08 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-22-010054 · doc4.xml · derivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2022 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 11:00 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-21-066283 · doc4.xml · derivative · entry 2 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,500 Underlying: Common Stock · 22,500 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vest in full on December 31, 2020, subject to Reporting Person's continuous service through December 31, 2020, subject to acceleration of vesting provided in the Employment Agreement, dated as of September 1, 2020, by and between the Issuer and the Reporting Person. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 11:00 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Exercise / conversionCommon Stock | 22,500 | $0.56 | $12,600.00 |
DisclosureSEC source: 0001209191-21-066283 · doc4.xml · nonDerivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2021 Filed May 27, 2021 20:36 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-21-036254 · doc4.xml · derivative · entry 2 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 25,000 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vest in full on December 31, 2020, subject to Reporting Person's continuous service through December 31, 2020, subject to acceleration of vesting provided in the Employment Agreement, dated as of September 1, 2020, by and between the Issuer and the Reporting Person. Read SEC document |
| May 26, 2021 Filed May 27, 2021 20:36 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Exercise / conversionCommon Stock | 25,000 | $0.56 | $14,000.00 |
DisclosureSEC source: 0001209191-21-036254 · doc4.xml · nonDerivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:33 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $7.83 | $0.00 |
DisclosureSEC source: 0001209191-21-024790 · doc4.xml · derivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of April 1, 2021 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| January 22, 2021 Filed Jan 25, 2021 21:24 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantCommon Stock | 8,000 | $6.00 | $48,000.00 |
DisclosureSEC source: 0001209191-21-005082 · doc4.xml · nonDerivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F1 · kind: Acquired from the Issuer pursuant to an Underwriting Agreement dated January 20, 2021 with a closing date of January 22, 2021. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:53 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-20-049303 · doc4.xml · derivative · entry 2 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-09-01 F2 · derivative.exercise_date: The shares vest in full on December 31, 2020, subject to Reporting Person's continuous service through December 31, 2020, subject to acceleration of vesting provided in the Employment Agreement, dated as of September 1, 2020, by and between the Issuer and the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 16:53 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-20-049303 · doc4.xml · derivative · entry 1 Stewart Christopher P. · CIK 0001822991 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-09-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on September 1, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such applicable vesting date and the terms of the Issuer's 2020 Inducement Plan, subject to acceleration of vesting as provided for in that certain Employment Agreement, dated as of September 1, 2020, by and between the Issuer and the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.